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Abstract: Breast cancer is a worldwide disease resulting in many deaths. Although breast 
cancer incidence is lower in Sub-Saharan African countries than in developed countries, 
African women are more likely than women in the developed world to be diagnosed at later 
stages of the disease and, thus, are more likely to die from it. This is due to the lack of 
awareness by women, accessibility to screening methods, and availability of African-based 
research findings that would influence decision making at the governmental level. This 
descriptive study was undertaken to shed light on the type, stage and age distribution of breast 
cancer at diagnosis in women living in central Sudan encompassing al-Gezira, Blue Nile, 
White Nile, and Sennar States. Cases comprised 1255 women from central Sudan diagnosed 
with breast cancer and referred to and treated at Institute of Nuclear Medicine, Molecular 
  Biology, and Oncology, from January 1999 to December 2006. Data revealed that 74% of 
the women were 50 years old or premenopausal. Invasive ductal carcinoma was the most 
common pathology (82%) and women presenting with stage III or higher tumors that had 
already metastasized, while ductal carcinoma in situ was the least prevalent (0.5%) finding. 
Estrogen and progesterone receptors expression were performed on a limited number of 
samples and the overwhelming majority of cases were observed to be negative for estrogen 
and progesterone receptors expression.
Keywords: female breast cancer, estrogen receptor, progesterone receptor, epidemiology, 
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Introduction
Breast cancer is the most commonly diagnosed cancer in women worldwide, and 
is second only to lung cancer as the leading cause of cancer deaths.1 Although, the 
incidence of breast cancer in Sub-Saharan African counties is low compared that in 
developed countries,2 the cancer picture in Sub-Saharan Africa and especially in Sudan 
is changing. Lately, breast cancer incidence and mortality has been rising.
Breast cancer in African women is characterized by younger age at onset, advanced 
stage at diagnosis, and consequently poor prognosis. For example in Nigeria, about 
two-thirds of women with breast cancer present with advanced stage disease.3,4 The 
reason for these unfavorable breast cancer presentations is reported to be the delay by 
patients presenting to the hospitals, due to ignorance, superstition, a skeptical attitude 
towards western medicine, and dependency on traditional medicine,5,6 in contrast to the 
industrialized world where early detection by mammographic screening and greater 
awareness by women has resulted in early detection. Early detection plus adjuvant 
chemotherapy has greatly increased survival rates for breast cancer patients.International Journal of Women’s Health 2010:2 78
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In the developed world assessment of hormonal 
  receptors expression status is required to determine patient 
  eligibility for hormonal therapy. However, in the developing 
  countries clinicians administer hormonal therapy without 
any knowledge of their patient’s receptors status. Estrogen 
receptors (ER) and progesterone receptors (PR) expression 
status is not routinely determined in the developing countries 
because of limited resources and the relatively high cost of 
testing. However, it should be noted that in a few studies 
conducted in Africa that examined ER and PR expression 
status, most African women were observed to have estrogen 
and progesterone negative tumors.7–9
This descriptive study was undertaken to shed the light 
on the type, stage and age distribution of breast cancer at 
diagnosis in women living in central Sudan encompassing 
al-Gezira, Blue Nile, White Nile, and Sennar States.
Material and methods
The central region of Sudan comprises four states including 
Blue Nile, al-Gezira, Sennar, and White Nile. Each of these 
states has population ranging from 600,000 to 3,797,000, 
the majority living in the capital regions and the rest in 
surrounding rural areas. Breast cancer cases diagnosed 
in these states are referred for treatment to the Institute 
of Nuclear Medicine, Molecular Biology and Oncology 
(INMO) at Gezira University located in Wadmedani in al-
Gezira State. Data presented in this study were collected 
from medical reports from these patients (N = 1255) 
referred to and treated at the INMO during the period 
January 1999 to December 2006. Data were entered into 
a computerized database with the approval of the INMO 
Institution Review Board.
Pathology evaluation
Data on age at diagnosis, tumor pathology, stage of dis-
ease, and patient residence (urban/rural), were recorded. 
Tumors were classified according to TNM classification 
which based on size of the primary tumor and presence 
of metastatic regional lymph nodes and/or of distant 
metastases. No data on grade were available (this was 
not a common service at that time at these local facili-
ties). Whenever possible, tumor specimens were stained 
immunohistochemically for estrogen and progesterone 
receptor expression.
Immunohistochemistry (IHC)
Immunohistochemistry was done according to the standard 
avidin–biotin–peroxidase complex method. Briefly, 
  histologic sections (5 Am) with neoplastic breast tissue 
were cut from formalin-fixed, paraffin-embedded tissues 
and mounted on positively charged Superfrost slides 
(Fisher Scientific). Tissue sections were deparaffinized and 
  rehydrated in graded ethanol. Antigens were retrieved by 
steaming in 0.01 mol/L citrate buffer (pH 6.0) in a water bath 
at 95°C for 10 min. Tissues were then blocked for endogenous 
peroxidase in 3% hydrogen peroxide in methanol and for 
nonspecific binding in tris buffered saline containing 0.3% 
Triton X-100, 0.2% saponin, and 0.5% blocking agent (NEN 
Life). Tissues were incubated overnight at 4°C in the follow-
ing antisera: ER-a monoclonal mouse anti-human antibody 
(ID5) at 1:25 dilution, progesterone receptor antibody (IA6) 
at 1:40 dilution (Novocastra Ltd) followed by biotinylated 
horse anti-mouse or goat anti-rabbit secondary antibodies 
(Vector Laboratories).
The chromogen was 3,3-diaminobenzidine (Vector 
Laboratories). Sections were counterstained in hematoxylin 
(Richard Allen Scientific) and then coverslipped in 50:50 
xylene/permount (Fisher Scientific).
All slides were reviewed independently. Expression of 
ER and PR in tumor tissues was analyzed and reported as 
the percentage of epithelial cells with positive staining. The 
  intensity of ER and PR immunostaining was graded on a scale 
of 0 to 3 where 0 = no staining, 1 = weak staining, 2 = moderate 
staining, and 3 = strong staining.
Statistical analysis
Morphologic lesions were expressed with descriptive sta-
tistics. Immunohistochemical data were analyzed with non-
parametric methods on semi-quantitative IHC scores using 
SPSS statistical software
Results
Age
Of the 1255 women treated at the INMO between the 
period 1999 to 2006, 279 (22.23%) were between ages 
35 and 40 years. About 927 of the 1255 (74%) breast 
cancer patients were premenopausal (age 50 years) 
while only 26% were postmenopausal (older than 50 
years) (Figure 1).
Tumor histopathology
Infiltrating ductal carcinoma constituted the majority of 
the breast cancers diagnosed (1029 of 1255; 82%). Other 
subtypes of breast disease such as infiltrating medul-
lary ductal carcinoma, infiltrating lobular carcinoma, 
  malignant connective tissue tumor, infiltrating mucinous International Journal of Women’s Health 2010:2 79
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ductal carcinoma, infiltrating papillary ductal carcinoma, 
as well as ductal carcinoma in situ, malignant phylloide 
tumor, infiltrating squamous cell carcinoma, and carcinoid 
tumor represented a small fraction of the diagnosed breast 
diseases (Table 1).
Tumor stage
According to the TNM staging criteria the majority of women 
presented with late disease that had already metastasized IV 
(T4N4M1; 24.6%), IIIA (T3N2M0; 18.0%), IIIB (T4N4M0; 
18.1%), IIA (T2N0M0; 8.2%), IIB (T3N0M0; 19.3%),   
I (T1N0M0; 11.3%), 0 (0.5%) (Figure 2). About 726 of the 
1255 (58%) women resided in rural areas and 529 of 1255 
(42%) women in the State capitals or surrounding areas 
(urban areas). Women living in the rural areas presented 
significantly more often with advanced metastatic disease 
stage III or higher (P = 0.002) than women living in urban 
areas (Figure 3).
Estrogen and progesterone receptor 
status
Information on ER and PR status was available for only 
50 patients. Tumor tissues were found to be predominantly 
estrogen negative (34/50; 68%) or progesterone negative 
(35/50; 70%). A smaller percentage of cases presented as 
ER-positive and PR-positive (10/50; 20%). ER and PR status 
could not be determined in 2 cases.
Discussion
Despite the fact that breast cancer has been reported to 
be the leading malignancy according to estimate data 
from GLOBOCAN,10 studies on breast cancer in Sudan 
have been limited. The reasons for this include the lack of   
Table 1 Histopathological characteristics of breast cancer in 
women from central Sudan
Histological type N %
Invasive ductal carcinoma 1029 82.0
Infiltrating medullary ductal carcinoma 91 7.3
Infiltrating lobular carcinoma 79 6.3
Malignant connective tissue tumor 14 1.1
Infiltrating mucinous ductal carcinoma 13 1.0
Malignant phylloide tumor 9 0.7
Infiltrating papillary ductal carcinoma 7 0.6
Ductal carcinoma in situ 6 0.5
Infiltrating squamous cell carcinoma 5 0.4
Carcinoid tumor 2 0.2
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Figure 1 Breast cancer age distribution (N = 1255). This graph shows age distribution of breast cancer in central Sudan. Women in central Sudan diagnosed with breast cancer 
were premenopausal (age 50 years) while only 26% were postmenopausal (older than 50 years).International Journal of Women’s Health 2010:2 80
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population-based cancer registry as well as lack of research 
resources (manpower and financial). The current study 
  analyzed and presented data collected at the local medi-
cal facilities in the Sudan and entered in computerized 
  database at the INMO when women were referred and 
treated at the Institute. While our study population is far 
from comprehensive it is thought to represent the totality 
of breast cancer in this area. Data on 1255 patients treated 
between 1999 and 2006 were examined. Of the 1255 patients 
examined we found that 74% were premenopausal women 
(aged 50 and younger) and 26% were postmenopausal, 
indicating early onset of breast cancer in women living in 
that area. This observation is consistent with the literature 
and has been reported in several other studies conducted in 
sub-Saharan Africa.11–13 A higher incidence of breast cancer 
in younger women has also been observed in women of 
African descent residing in western countries.14,15 Similarly, 
in a recent study conducted to examine data collected from 
British women, it has been shown that black British women 
were diagnosed with breast cancer at a much younger age 
(average difference 21 years) compared to their white coun-
terparts.16 The reasons for the younger age distribution of 
African women with breast cancer deserve additional study. 
However, Pathak et al17 investigated this issue in African-
American women living in the United States. Pathak and his 
colleagues correlated the short-term increase in breast cancer 
risk occurs in the postpartum period with premenopausal 
breast cancer risk and concluded that the higher prevalence 
of early childbearing among African-American when com-
pared with Caucasian-American women may account for 
the higher incidence of early-onset breast cancer. In another 
study Palmer et al18 reported that multiparity increased breast 
cancer risk prior to age 45 but offer a protective effect after 
age 45 years. These factors may explain the age distribution 
of breast cancer in African women who tend to have multiple 
children at a younger age.
Infiltrating ductal carcinoma was the most common 
and ductal carcinoma in situ (DCIS) was among the least 
common histopathological diagnosis noted in this study. 
The majority (88.2%) of women presented with Stage III 
or higher tumors. This has also been observed in studies 
conducted in other African countries, wherein a majority 
of the cases were observed to be invasive ductal carci-
noma.13,19 These findings may be attributable to the fact 
that patients ignore symptoms and do not access medi-
cal care at an early date. This might be due to a lack of 
education, a skeptical attitude towards western medicine, 
cultural mores that ostracize and alienate diseased indi-
viduals, a dependency on traditional medicine,20 limited 
access to medical care (financial or otherwise), distance 
to the medical centers, availability of boarding and lodg-
ing close to the centers, the fear of being perceived as 
0
5
10
15
20
25
P
e
r
c
e
n
t
 
o
f
 
w
o
m
e
n
 
w
i
t
h
b
r
e
a
s
t
 
c
a
n
c
e
r
 
Stage
Stage 0
Stage I
Stage IIB
Stage IIIB
Stage IV
Stage IIA
Stage IIIA
Figure 2 Breast cancer by stage. The graph shows that women living in central Sudan present to the local medical facility with late stage tumors III and higher.International Journal of Women’s Health 2010:2 81
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a burden to relatives and friends, financial aspects of 
undergoing testing and treatment, and various other fac-
tors that play a role in prolonging the patients’ decision 
to seek medical treatment.21,22 Even if women managed 
to overcome all these challenges, there is still the issue 
of whether mammography and effective treatment will 
be available to them. These factors are compounded by 
a lack of governmental subsidies dedicated to improving 
diagnosis and treatment.
Hormone receptor status was available for only 50 patients 
(4%). The reason is that testing is performed at only one 
private laboratory. Patients are presented with their breast 
biopsy in a formalin jar and advised to take it to a labora-
tory in Khartoum for analysis. The laboratory is a 3-hour 
drive from INMO. The total cost for the bus ride, food and 
lodging, and laboratory analyses is equivalent to 1 month’s 
income for one Sudanese family. Very few women can afford 
this test so they simply take the sample home and bury it. 
Many of these women have been diagnosed with invasive 
metastatic cancers, have no money or prospects for treatment, 
and believe that spending more money on additional tests is 
a waste and is taking money away from the support of their 
family. Moreover, ER status means nothing to many of the 
physicians as these women present with late stage tumors 
that had metastasized.
For those women who did undergo additional hormonal 
testing, a high percentage of tumors were found to not express 
estrogen and progesterone receptors (ER-negative = 68%; 
PR-negative = 70%). This finding is similar to observations 
previously made in other African studies. One such 
study evaluating hormonal receptor status found that 
ER/PR-negative tumors were more predominant in breast 
cancer cases from Tanzania.23 Analysis of ER/PR status in 
Nigeria showed similar results wherein 75% of the cases 
presented with ER-negative and 72% of cases PR-negative 
tumors.24 Similar hormonal status expression was observed in 
  African-American women who presented with ER-negative 
tumors.25
In conclusion, this study suggests that the typical breast 
cancer patient in central Sudan tends to be a younger, 
  premenopausal woman living in a rural area and presenting 
with advanced disease likely to be ER/PR negative.
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